AnteoTech (ASX:ADO) share price surges amid ambition to join scramble for RATs

The AnteoTech share price has started today on the right foot.

| More on:
Health workers shake hands and congratulate each other on good news.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Key points

  • The AnteoTech share price is up 4% in early morning trade.
  • The gain may relate to reports AnteoTech's boss is hopeful its RAT device is in the final stages of TGA approval
  • The company's reportedly preparing to ramp up production in Australia on the back of the regulator's green light

The AnteoTech Ltd (ASX: ADO) share price is in the green this morning.

The gain comes amid reports AnteoTech plans to ramp up Australian production of its point-of-care rapid testing device as it awaits the Therapeutic Goods Administration's (TGA's) tick of approval.

At the time of writing, the AnteoTech share price is trading at 26.5 cents, 3.92% higher than its previous close.

AnteoTech shares climb as it readies for Australian approval

The AnteoTech share price is gaining after the company's CEO Derek Thomson told ABC News it's getting ready to hit the ground running as soon as its RAT is given the green light for use in Australia.

The Australia-based company is also reportedly prepared to push some of its tests produced in Spain into its home country until domestic manufacturing gets on its feet.

The ABC quoted Thomson as saying:

We can manufacture, currently, a small volume of tests here…

Our plan now, as Australian governments have indicated that RATs are going to be a frontline tool for the pandemic, is to scale up manufacturing here in Brisbane significantly over the next 9 to 12 months.

AnteoTech's RAT works through its EuGeni Rapid Diagnostic Platform. It's a point-of-care platform – meaning it can be operated by healthcare professionals. The company's COVID-19 RAT is the first test to be used with EuGeni.

Thomson said AnteoTech had put an order in for equipment that could see it producing 12 million RAT strips annually in Australia. It expects production to start in the second quarter of 2022.

Additionally, he told the publication AnteoTech would be able to make more than that 12 million over the next 12 months, providing "a real sovereign manufacturing capability for the Australian market".

Finally, Thomson noted the company's tests could be in the final stages of TGA approval. He said AnteoTech was planning to supply more information to the regulator next week.

Spotlight on RATs

There's plenty of other news likely putting the focus on RAT developers today.

Overnight, United States President Joe Biden announced the government will soon hand out 1 billion at-home RATs – meaning they'll be out shopping for an additional 500 million tests.

Meanwhile, controversy surrounding the Australian Federal Government's acquisition of RATs hit headlines today. If reports are correct, demand for RATs at retail outlets may well increase.

According to yesterday's reporting by SBS, retailers claim the government seized their RAT orders at the point of import. The Department of Health has denied diverting supplies.

AnteoTech share price snapshot

The AnteoTech share price has had a rough start to 2022. Prior to today's open, it had fallen 17% since the final close of last year.

However, shares in the company are currently trading 120% higher than this time last year.

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on Healthcare Shares

Doctor doing a telemedicine using laptop at a medical clinic
Healthcare Shares

The Mesoblast share price just rocketed 38%! Here's why

ASX investors just sent the Mesoblast share price up 38%. But why?

Read more »

couple having a happy discussion with a banker
Healthcare Shares

Expert: 4 ASX healthcare stocks to buy ahead of reporting season

Could these ASX healthcare stocks be good additions to your portfolio?

Read more »

Excited couple celebrating success while looking at smartphone.
Healthcare Shares

Guess which ASX 200 stock just jumped 9% on big news

Let's find out what is getting investors excited today.

Read more »

Male doctor in a lab coat working at laptop looking serious.
Healthcare Shares

What are Cochlear shares worth according to Macquarie?

Let's see what the broker is saying about this blue chip.

Read more »

Shot of a mature scientists working on a laptop in a lab.
Healthcare Shares

When will CSL shares finally catch a break?

Here's where analysts think the biotech stock is heading next.

Read more »

An analyst wearing a dark blue shirt and glasses sits at his computer with his chin resting on his hands as he looks at the CBA share price movement today
Healthcare Shares

JP Morgan initiates coverage of Telix Pharmaceuticals. After rising 1,667% in 5 years, is it still a buy?

Can this ASX 200 juggernaut go higher?

Read more »

Cropped shot of an attractive young female scientist working on her computer in the laboratory.
Healthcare Shares

Why this top broker expects CSL shares to surge 26%

A leading broker foresees a big rebound ahead for CSL shares. But why?

Read more »

Man jumps for joy in front of a background of a rising stocks graphic.
Healthcare Shares

Guess which ASX All Ords stock is jumping on big US news

This small cap is catching the eye on Thursday. But why?

Read more »